In a September 7, 2026 interview with the BBC, Arm Holdings CEO Rene Haas stated that current AI systems lack the computational capacity to model complex interactions between cancer and DNA. He characterized the semiconductor industry as being in a state of supply constraints, which hinders progress in AI-driven drug discovery and medical research.
Haas, who served on the board of AstraZeneca until April 2026, views healthcare as a primary application for artificial intelligence. Despite existing hardware limitations, he remains optimistic that advancements in computing will eventually enable breakthroughs in cancer treatment within the current generation.
Arm continues to expand its influence in the hardware sector, having shipped over 350 billion chips globally. The company is shifting its focus toward data centers, which Haas anticipates will become its largest business segment. In March 2026, Arm introduced its AGI CPU line, specifically engineered to handle AI-optimized workloads.
